[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-383758-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-383758-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cancer-associated-macrophage-like-cells-in-metastatic-renal-cell-carcinoma-predicts-for-poor-prognosis-and-tracks-treatment-response-in-real-time","Cancer associated macrophage-like cells in metastatic renal cell carcinoma predicts for poor prognosis and tracks treatment response in real time","","Renal cell carcinoma (RCC) has a high mortality rate, and metastatic RCC outcomes remain limited by treatment resistance and toxic side effects. Current blood-based biomarkers such as white blood cells, hemoglobin, and platelets provide restricted prognostic value. Cancer associated macrophage-like cells (CAMLs) offer a potential biomarker because their number and size relate to poor clinical outcomes. In blood samples from 40 RCC patients, CAML changes were monitored during treatment to assess real-time predictive and prognostic utility, showing smaller CAMLs associated with better progression-free and overall survival.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cancer-associated-macrophage-like-cells-in-metastatic-renal-cell-carcinoma-predicts-for-poor-prognosis-and-tracks-treatment-response-in-real-time/383758/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cancer-associated-macrophage-like-cells-in-metastatic-renal-cell-carcinoma-predicts-for-poor-prognosis-and-tracks-treatment-response-in-real-time/383758.png","ImageObject",300,407,{"name":42,"@type":43},"Jacob","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role do cancer associated macrophage-like cells (CAMLs) play in metastatic renal cell carcinoma?","Question",{"text":63,"@type":64},"CAMLs are proposed as a biomarker in metastatic renal cell carcinoma because their number and size in peripheral blood have been linked to poor patient outcomes. The study evaluates their clinical utility by tracking CAML changes during therapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were CAMLs evaluated to predict treatment outcomes in this study?",{"text":68,"@type":64},"Blood samples from 40 RCC patients were collected, and CAML changes were monitored across treatment regimens. This monitoring was used to assess whether CAMLs could predict treatment efficacy and survival outcomes.",{"name":70,"@type":61,"acceptedAnswer":71},"What survival differences were associated with CAML size?",{"text":72,"@type":64},"Patients with smaller CAMLs showed better progression-free survival and overall survival than patients with larger CAMLs. The reported hazard ratios and p-values indicate statistically significant associations.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},383758,1790718971,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nCancer associated macrophage‑like cells in metastatic renal cell carcinoma predicts for poor prognosis and tracks treatment response in real time  \nAmama Ali1, Daniel L. Adams1*, Dimpal M. Kasabwala1, Cha‑Mei Tang2 & Thai H. Ho 3  \nRenal Cell Carcinoma (RCC) is a fatal urological cancer, with one third of patients diagnosed with metastasis, resulting in a 5‑year survival of only 12% . Recent advancements in therapies have increased survival in mRCC, but lack efficacy in subtypes, due to treatment resistance and toxic side effects. Currently, white blood cells, hemoglobin, and platelets are limitedly used as blood based biomarkers to help determine RCC prognosis. Cancer associated macrophage‑like cells (CAMLs) are a potential mRCC biomarker which have been identified in peripheral blood of patients with malignant tumors and have been shown to predict poor clinical patient outcomes based on their number and size. In this study, blood samples from 40 RCC patients were obtained to evaluate the clinical utility of CAMLs. CAML changes were monitored during treatment regimensto evaluate their ability to predict treatment efficacy. It was observed that patients with smaller CAMLs had better progression free survival (HR = 2.84, 95% CI 1.22–6.60, p = 0.0273) and overall survival (HR = 3.95, 95% CI 1.45–10.78, p = 0.0154) versus patients with larger CAMLs. These findings suggest that CAMLs can be used asa diagnostic, prognostic, and predictive biomarker for patients with RCC which may help improve management of advanced RCC.  \nAbbreviations  \nRCC Renal cell carcinoma  \nmRCC Metastatic renal cell carcinoma ccRCC Clear cell renal cell carcinoma  \nMTSCC Mucinous tubular and spindle cell carcinoma CAML Cancer associated macrophage-like cell PFS Progressive free survival  \nOS Overall survival  \nHR Hazard ratio  \nCI Confidence interval  \nIMDC International mRCC database consortium IRB Institutional review board  \nWBC White blood cell  \nRenal cell carcinoma (RCC), the 8th most common cancer, forms from renal tubular epithelial cells and makes up over 80% of all kidney cancers, with clear cell RCC being the largest subtype1,2. RCC affects ~ 79,000 individuals in the United States and results in ~ 13,900 deaths annually with incidence in men being 50% higher than in women and more common in people over the age of 60 years old3,4. The most common genetic cause for RCCis a disease of the Von-Hippel Lindau gene, while established non-genetic factors include smoking, obesity, hypertension, and chronic kidney disease4. In the past two decades, approximately 50% of RCC diagnoses were  \n1Creatv Bio, Division of Creatv MicroTech, Inc., 9 Deer Park Dr, Monmouth Junction, NJ 08852, USA. 2Creatv Bio, Division of Creatv MicroTech, Inc., 9900 Belward Campus Dr., Rockville, MD 20850, USA. 3Division of Hematology/Oncology, Mayo Clinic Arizona, 5777 East Mayo Boulevard, Phoenix, AZ 85054, USA. *email: dan@ [creatvmicrotech.com](creatvmicrotech.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nmade due to incidental detection through newer imaging technologies resulting in ~ 33% RCC diagnoses being made at the metastatic stage4.  \nThe International mRCC Database Consortium (IMDC) risk calculator is a well-established tool which can help predict survival outcomes in mRCC patients3,5. The IMDC uses multiple factors (hemoglobin level, time from diagnosis to start of treatment, neutrophil count, etc.) to determine whether a patient is in a good, intermediate, or a poor-risk grouping3,5. The patient’s categorical estimate can help doctors determine the type of first line therapy to use on patients5. To treat RCC, surgery is still the first choice for treating non-metastasized disease, while systemic targeted therapies (i.e. Pazopanib, Axitinib, etc.), and more currently PD-1 inhibiting immunotherapies (i.e. Nivolumab, Ipilimumab, etc.), are used as neoadjuv","cbCaidlTLzckfpR2","https://ap.wps.com/l/cbCaidlTLzckfpR2","pdf",1810933,"English","# Background\n## Limitations of existing blood biomarkers\n## Treatment context and resistance\n# CAMLs as candidate biomarkers\n# Methods\n## Patient cohort and blood sampling\n## Monitoring CAMLs during treatment\n# Results\n## Association with progression-free survival\n## Association with overall survival\n# Implications\n## Diagnostic, prognostic, and predictive potential","[{\"question\":\"What role do cancer associated macrophage-like cells (CAMLs) play in metastatic renal cell carcinoma?\",\"answer\":\"CAMLs are proposed as a biomarker in metastatic renal cell carcinoma because their number and size in peripheral blood have been linked to poor patient outcomes. The study evaluates their clinical utility by tracking CAML changes during therapy.\"},{\"question\":\"How were CAMLs evaluated to predict treatment outcomes in this study?\",\"answer\":\"Blood samples from 40 RCC patients were collected, and CAML changes were monitored across treatment regimens. This monitoring was used to assess whether CAMLs could predict treatment efficacy and survival outcomes.\"},{\"question\":\"What survival differences were associated with CAML size?\",\"answer\":\"Patients with smaller CAMLs showed better progression-free survival and overall survival than patients with larger CAMLs. The reported hazard ratios and p-values indicate statistically significant associations.\"}]","Cancer associated macrophage-like cells in metastatic renal cell carcinoma predicts for poor prognosis and tracks treatment response in real time | PDF",1790259054,23]